Highest-materiality recent filing
Vir Biotechnology appoints Timothy Coughlin as new director and Audit Committee Chair
Board increased from 7 to 8 members; Timothy Coughlin appointed effective June 9, 2026.
Saira Ramasastry steps down from board and audit committee effective May 26, 2026, due to business conflict; no disagreement with company.
Vir Bio Q1 net loss $125.7M; cash $809.3M; positive CHD data; VIR-5500 collaboration closed
Net loss of $125.7M ($0.85 per share) vs $121M ($0.88) in Q1 2025.
Vir Biotechnology CMO Mark Eisner to step down effective April 24, 2026
Mark Eisner, EVP and Chief Medical Officer, leaving role on April 24, 2026.
Vir Bio appoints CEO Marianne De Backer to additional role of President
On March 4, 2026, Vir Bio's Board appointed CEO Marianne De Backer to the additional position of President.
Vir Biotechnology closes $172.5M equity offering; underwriters exercise full over-allotment
Sold 20,294,117 shares of common stock at $8.50 per share, raising ~$172.5M in gross proceeds.
Vir Biotechnology prices $150M public offering of 17.6M shares at $8.50/share
Offering of 17,647,059 shares of common stock at $8.50 per share; over-allotment option for 2,647,058 shares.
Vir Bio will receive $335 million in upfront and near-term payments, including $240M cash and $75M equity at 50% premium.
Vir Bio: 88% HDV RNA undetectable at Week 96 in combo arm; cash ~$781M, runway to Q4 2027
Phase 2 SOLSTICE: 88% (21/24) of combo arm achieved undetectable HDV RNA at Week 96 vs 46% (11/24) monotherapy.
Exclusive commercial license for tobevibart+elebsiran in Europe, Australia, New Zealand for chronic hepatitis delta.
Vir Biotech Q3 net loss $163M ($1.17/sh); ECLIPSE enrollment ahead of schedule
Net loss $163.1M ($1.17/sh) vs $213.7M ($1.56) in Q3 2024; revenues $0.2M.
Vir Biotechnology Q2 net loss $111.0M; cash $892.1M; ECLIPSE program underway
Net loss $111.0M ($0.80/share) vs $138.4M ($1.02) in Q2 2024; revenue $1.2M down from $3.1M.
First patient dosed in Phase 1 trial of VIR-5525, a dual-masked T-cell engager targeting EGFR, in solid tumors (NSCLC, CRC, HNSCC, cSCC).
Jeffrey S. Hatfield and Saira Ramasastry elected as Class III directors each with >93 million votes for.
Vir Biotech reports HBsAg loss in MARCH study but halts Phase 3 for chronic HBV without partner
HBsAg loss 24 weeks post-treatment: 17% (3/18) and 21% (3/14) in low baseline HBsAg patients with tobevibart+elebsiran without/with PEG-IFNα.
Vir Biotech Q1 net loss $121M; launches Phase 3 hepatitis delta program; cash into mid-2027
Net loss of $121.0M ($0.88 per share) vs $65.3M ($0.48) in Q1 2024; revenue $3.0M vs $56.4M.
Vir Biotechnology reports Q4 and full year 2024 financial results and pipeline updates
Cash, cash equivalents and investments of $1.10 billion as of Dec 31, 2024, providing cash runway into mid-2027.
Vir Biotechnology CTO to depart Feb 26; Maninder Hora appointed as replacement
Ann (Aine) M. Hanly, EVP and Chief Technology Officer, will leave Vir Biotechnology on February 26, 2025.
Vir Biotech reports encouraging Phase 1 data: 50% tumor shrinkage (VIR-5818), 58% PSA50 (VIR-5500)
VIR-5818 (HER2): 50% (10/20) tumor shrinkage at doses ≥400 µg/kg; cPR in 33% (2/6) HER2+ CRC.
Vir Biotech Q3 net loss $213.7M; closes Sanofi TCE licensing deal, appoints new CFO
Net loss $213.7M ($1.56 per share) vs $163.4M ($1.22) in Q3 2023; revenue $2.4M, down from $2.6M.
Vir closes $100M Sanofi license deal for three T-cell engagers; appoints new CFO
Closed exclusive worldwide license with Sanofi for 3 clinical-stage masked TCEs (SAR446309, SAR446329, SAR446368) and PRO-XTEN platform for oncology/infectious disease.
Vir Biotechnology licenses three clinical-stage masked T-cell engagers from Sanofi for $100M upfront
Upfront payment of $100M plus $75M escrowed milestone for SAR446368 (AMX-525) first-in-human dosing by 2026.
Vir Bio Q2 net loss narrows to $138M; initiates restructuring cutting 25% of workforce
Net loss of $138.4M ($1.02/sh) vs $194.8M ($1.45/sh) in Q2 2023; cash and investments $1.43B, down $78M in quarter.
Vir Biotech gets FDA IND clearance & Fast Track for hepatitis delta combo therapy
FDA cleared IND and granted Fast Track for tobevibart + elebsiran for chronic hepatitis delta.
Vir reports high virologic response in Phase 2 SOLSTICE hepatitis delta trial
De novo tobevibart+elebsiran combination: 64% (7/11) combined endpoint at week 24.
Vir Biotechnology shareholders elect Class II directors, approve advisory compensation, ratify EY
Directors De Backer, Bischofberger, Farid, Nelsen elected with votes for/withheld: 105.6M/1.1M, 80.0M/26.7M, 106.4M/0.3M, 67.9M/38.8M; broker non-votes 12.3M.
Vir Biotechnology Q1 net loss narrows to $65.3M; CFO stepping down; pipeline catalysts ahead
Net loss of $65.3M ($0.48 loss per share) vs $140.9M ($1.06) in Q1 2023; revenue $56.4M down 10.5% YoY.
CFO Sung Lee resigns effective May 3; board nominates two new independent directors
CFO Sung Lee resigns effective May 3, 2024, to pursue other opportunity; no disagreement with company.
Vir Biotech Q4/FY2023 net loss $116M/$615M; GSK flu pact ended; cash $1.63B
Q4 net loss $116.0M ($0.86 loss per share); FY2023 net loss $615.1M ($4.59 loss per share).
Vir Biotechnology CMO Phil Pang to leave at end of March 2024; successor search started
Executive VP and Chief Medical Officer Phil Pang, M.D., Ph.D. departing at end of March 2024, citing family reasons.
Vir Biotechnology to cut 12% of workforce, close R&D sites; charges $30-40M
Workforce reduction of ~75 positions (12%) and closure of St. Louis and Portland R&D facilities in 2024.
Vir Biotechnology enters $300M at-the-market equity facility with TD Cowen
New Sales Agreement allows Vir to sell up to $300M of common stock through TD Cowen as agent.
Vir Biotechnology Q3 net loss $163.4M; revenue down 99% YoY on sotrovimab sales decline
Net loss of $163.4M ($1.22/share) vs net income of $175.3M ($1.32/share) in Q3 2022.
Vir Biotechnology receives $50M from BARDA for next-gen COVID-19 mAb and pandemic preparedness
BARDA awards $40M via Project NextGen for VIR-7229 Phase 1 trial, expected completion H2 2025.
Vir Biotechnology COO Johanna Friedl-Naderer to depart Sept 29; role not replaced
EVP and COO Johanna Friedl-Naderer will leave Vir Biotechnology on September 29, 2023.
Vir Biotech Q2 net loss $194.8M; hep B/delta data on track for Q4
Net loss $194.8M ($1.45/sh) vs $76.5M loss YoY; revenues $3.8M (incl $16.5M grant).
Vir Bio Phase 2 flu prevention trial misses endpoints; cash ~$1.9B
Phase 2 PENINSULA trial of VIR-2482 did not meet primary or secondary efficacy endpoints for preventing symptomatic influenza A.
Vir Biotechnology annual meeting: directors elected, say-on-pay and auditor ratified
Stockholders elected Robert More, Janet Napolitano, Vicki Sato, and Elliott Sigal as Class I directors; each received over 98M votes for.
Vir Biotech Q1 revenue $63M (down 95% YoY); net loss $140.9M; new CEO Marianne De Backer
Q1 2023 total revenues $63M vs $1.2B in Q1 2022 (-94.9%); net loss of $140.9M ($1.06/sh) vs net income of $518.6M.
Vir Biotechnology discloses $220M exposure to Silicon Valley Bank after FDIC seizure
FDIC took control of Silicon Valley Bank (SVB) on March 10, 2023.
Eliminated requirement to make stockholder list available at meeting; added adjournment for technical failure.
Vir Biotech Q4 net loss $101.6M; CEO Scangos retiring, CFO Horn resigning
Q4 2022 revenue $49.4M vs $812.7M YoY; net loss $0.76/share vs net income $4.01/share.
NICE recommends Vir's sotrovimab for COVID-19 in UK; no meaningful 2023 sales expected
NICE final draft guidance recommends sotrovimab for high-risk adults where Paxlovid is contraindicated or unsuitable.
Vir Biotechnology names Sung Lee CFO, replacing Howard Horn effective March 27
Sung Lee appointed EVP and CFO effective March 27, 2023; Howard Horn steps down as CFO but remains EVP through April 28.
Vir Bio amends GSK deal: regains full rights to vaccine program, narrows antibody program
Amendments remove CoV Vaccine Program from collaboration; Vir retains rights to progress independently.
Vir Biotechnology appoints Marianne De Backer as CEO effective April 3, 2023; George Scangos retires
George Scangos notified Board of retirement as CEO and President, effective April 3, 2023.
Vir Biotech Q3 revenue $374.6M; BARDA contract up to $1B; Phase 2 data in 2023
Q3 2022 revenue $374.6M (vs $103.6M YoY); net income $175.3M ($1.32 basic EPS) vs $110.4M ($0.85) in Q3 2021.
Vir Biotechnology awarded up to $1B BARDA contract for influenza and pandemic preparedness
BARDA to invest ~$55M initially for VIR-2482 (influenza prophylactic mAb) development through Jan 2026.
Vir Q2 net loss $76.5M; revenue negative on $397.4M non-cash charge; >$2.6B cash
Net loss of $76.5M ($0.58 per share) vs net income of $61.8M ($0.48) in Q2 2021.
Vir Biotechnology delays Q2 2022 earnings release to Aug 9, 2022 to finalize results
Company will issue Q2 2022 earnings release on August 9, 2022 after market close.
the appointment of Timothy Coughlin, CPA, to fill the newly created vacancy and serve on the Board as a Class III director until the Company's 2028 annual meeting of stockholders, as well as the appointment of Mr. Coughlin as Chair of the Audit Committee of the Board, in each case effective immediately.
On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, effective May 26, 2026.
On January 24, 2025, Vir Biotechnology, Inc. (the “Company”) announced that Ann (Aine) M. Hanly, Ph.D., the Company’s Executive Vice President and Chief Technology Officer, will be leaving the Company on February 26, 2025.
The Company has appointed Maninder Hora, Ph.D. to the role of Executive Vice President and Chief Technical Operations Officer, effective February 27, 2025, and Dr. Hora will assume Dr. Hanly’s responsibilities.
the Company announced that Jason O’Byrne, MBA, has been appointed as Executive Vice President and Chief Financial Officer and “principal financial officer” of the Company, effective as of October 2, 2024
On April 15, 2024, Sung Lee, Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc. (the “Company”), informed the Company that he will be stepping down from his role, effective May 3, 2024, to pursue another career opportunity.
On February 20, 2024, Vir Biotechnology, Inc. (the “Company”) announced that Executive Vice President and Chief Medical Officer, Phil Pang, M.D., Ph.D. has decided to leave the Company at the end of March 2024 to spend more time with his family.
On September 20, 2023, Vir Biotechnology, Inc. (the “Company”) announced that Johanna Friedl-Naderer, the Company’s Executive Vice President and Chief Operating Officer, will be leaving the Company on September 29, 2023.
On February 13, 2023, the Board of Directors (the “Board”) of Vir Biotechnology, Inc. (the “Company”) appointed Sung Lee as Executive Vice President and Chief Financial Officer of the Company, effective as of March 27, 2023 (the “Effective Date”).
Howard Horn will step down as Chief Financial Officer of the Company effective upon Mr. Lee’s appointment on the Effective Date, and will remain with Vir as Executive Vice President until April 28, 2023, to assist with the transition.
In addition, effective as of the Effective Date, the size of the Board will increase to 11 directors and Dr. De Backer will be appointed to fill the newly created vacancy to serve on the Board as a Class II director until the Company’s 2024 annual meeting of stockholders, and until her successor is duly elected and qualified, or until her earlier death, resignation or removal.
On January 19, 2023, George Scangos, Ph.D., notified the Board of Directors (the “Board”) of Vir Biotechnology, Inc. (the “Company”) of his decision to retire as Chief Executive Officer and President effective as of the Effective Date (as defined below).
Max materiality 0.95 · Median 0.65 · Most common event other_material